ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
RETRACTED: LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.BMC cancer · 2021Pooled it
- Retraction: LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR5095p to modulate FOXP1 expression.Oncotarget · 2026Article
- Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy.Genes & diseases · 2025Review
- MiR-3202-DTL signaling axis impedes NSCLC malignancy via regulating the ubiquitination-proteasome degradation of p21.Molecular and cellular biochemistry · 2025Article
- Exploring the roles of non-coding RNAs in liver regeneration.Non-coding RNA research · 2024Review
- Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024Review
- Insights about exosomal circular RNAs as novel biomarkers and therapeutic targets for hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- Tumor-derived exosomal linc00881 induces lung fibroblast activation and promotes osteosarcoma lung migration.Cancer cell international · 2023Article
- Combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 as a novel clinical biomarker used to predict prognosis in patients with osteosarcoma.Experimental and therapeutic medicine · 2023Article
- LncRNA LBX2-AS1 impacts osteosarcoma sensitivity to JQ-1 by sequestering miR-597-3p away from BRD4.Frontiers in oncology · 2023Article
- Long non-coding RNA DUXAP10 exerts oncogenic properties in osteosarcoma by recruiting HuR to enhance SOX18 mRNA stability.Human cell · 2022Article
- LncRNAs and CircRNAs in cancer.MedComm · 2022Review
- LINC01128 facilitates the progression of pancreatic cancer through up-regulation of LDHA by targeting miR-561-5p.Cancer cell international · 2022Article
- Article
- Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients.Cancers · 2022Article
- Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.Frontiers in immunology · 2022Review
- Long non-coding RNA HCG11 enhances osteosarcoma phenotypes by sponging miR-1245b-5p that directly inhibits plakophilin 2.Bioengineered · 2022Article
- lncRNA MELTF-AS1 facilitates osteosarcoma metastasis by modulating MMP14 expression.Molecular therapy. Nucleic acids · 2021Article
- Noncoding RNAs in tumor metastasis: molecular and clinical perspectives.Cellular and molecular life sciences : CMLS · 2021Review
- DUXAP8 knockdown inhibits the development of melanoma by regulating the miR-3182/NUPR1 pathway.Oncology letters · 2021Article
Corrections and comments
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article has been retracted: please see Elsevier policy on Article Correction, Retraction and Removal (https://www.elsevier.com/about/policies-and-standards/article-withdrawal). This article has been retracted at the request of the the editor-in-chief. A reader communicated concerns to the editorial office. These concerns are also echoed in a Pubpeer thread (https://pubpeer.com/publications/D9519B92998E6AD186E49846F789C4) where readers drew attention to similarities between figures within this article. Image analysis performed by the editorial office revealed evidence of image duplication within Figures 2D, 2E, 4C, 6C, and 6D of this article. Evidence of image recycling was also found between images in Figures 3J, 4B, and 6B of this article and an article in Oncotarget by the same authors (Zhu et al., 2017, Oncotarget 8, 71881-71893, https://doi.org/10.18632/oncotarget.17985). This reuse of data without appropriate attribution represents a severe abuse of the scientific publishing system. The authors did not agree to retract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.